$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer
04:55am, Wednesday, 02'nd Oct 2024
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.
3 Dirt Cheap Stocks to Buy Right Now
07:36am, Saturday, 21'st Sep 2024
CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
06:56pm, Thursday, 19'th Sep 2024
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
04:33am, Thursday, 19'th Sep 2024
CRISPR Therapeutics is in the process of building out a network of clinics. As those clinics open up, it'll be able to realize more revenue from its therapy.
Crispr Therapeutics: Prepare To Be Bored
09:11am, Wednesday, 18'th Sep 2024
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT,
1 Biotech Stock Down 62% to Buy and Hold
08:45am, Thursday, 12'th Sep 2024
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
04:15am, Thursday, 12'th Sep 2024
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have decline
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
06:55pm, Tuesday, 10'th Sep 2024
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.
2 Biotech Bets to Buy in September
12:32pm, Sunday, 08'th Sep 2024
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?
08:45am, Thursday, 05'th Sep 2024
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improve
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
12:35pm, Wednesday, 04'th Sep 2024
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
3 Monster Biotech Stocks to Buy Before 2025
06:15pm, Monday, 02'nd Sep 2024
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
07:30am, Monday, 26'th Aug 2024
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
12:46pm, Monday, 19'th Aug 2024
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Crispr's Casgevy Launch: Promising Start, Uncertain Future
06:08am, Wednesday, 14'th Aug 2024
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy,
Sign In
Buy CRSP